# Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

> **NCT03201146** · PHASE1,PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Lung Cancer
- Non Small Cell Lung Cancer
- Combination Chemotherapy
- Apatinib

## Interventions

- **DRUG:** Apatinib
- **DRUG:** AP or AC
- **DRUG:** Apatinib 250mg
- **DRUG:** Apatinib 500mg
- **DRUG:** Apatinib 750mg

## Key facts

- **NCT ID:** NCT03201146
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-27
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201146, "Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03201146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*